Contributors

Glaxo Laboratories

Publication/Creation

1969.

Persistent URL

https://wellcomecollection.org/works/wykr358k

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection 183 Euston Road London NW1 2BE UK T +44 (0)20 7611 8722 E library@wellcomecollection.org https://wellcomecollection.org

Betnovate

Rectal Preparations the classic haemorrhoidal therapy

novate

the fast, effective, economical rectal preparations

Effectiveness Betnovate Rectal Ointment contains 0-05% betamethasone 17-valerate—the most successful topical corticosteroid. Betamethasone gives quicker and more effective treatment in relatively responsive conditions and can often succeed when other topical corticosteroids fail.^{1,1,3}

Each Betnovate Compound Suppository contains 0.5 mg betamethasone 17-valerate, with 40-0 mg of the local analgesic lignocaine hydrochloride for rapid relief of pain. In order to constrict swollen blood vessels, minimise bleeding and to prolong the effect of the lignocaine 2-0 mg of the vasoconstrictor phenylephrine hydrochloride is included. Betnovate Rectal Ointment contains 0-05% betamethasone 17-valerate, 2-5% lignocaine hydrochloride and 0-1% phenylephrine hydrochloride.

Lowest cost Betnovate Rectal Ointment is the least expensive corticosteroid-containing rectal ointment. At low cost you can now prescribe a most effective

preparation for the treatment of external and internal haemorrhoids, anal fissures and minor ano-rectal disorders associated with haemorrhoids. Betnovate Suppositories complete the range of low-cost anti-haemorrhoidal preparations.

1. Arch. Derm. (1967) **95**, 514 2. Brit. med. J. (1967) **4**, 275 3. Lancet (1964) **1**, 1,177

For your detailed reading

For your detailed reading Betnovate rectal preparations Betnovate Rectal Ointment and Betnovate Compound Suppositories usually provide a high degree of relief from pain and bleeding associated with haemorrhoids, anal fissures and mild ano-rectal disorders such as pruritus, peri-anal eczema and mild proctitis. The efficacy of the Betnovate rectal preparations can be attributed to the powerful local anti-inflammatory activity of the topical corticosteroid betamethasone 17-valerate, the analgesic effect of lignocaine, and the vasoconstrictor effect of

phenylephrine. Apart from minimising any bleeding phenylephrine prolongs the duration of local analgesia.

Indications Pain and bleeding associated with anal fissures and internal or external haemorrhoids. Post-haemorrhoidectomy pain Ano-genital pruntus Minor degrees of proctitis

Precautions Conticosteroids should not be used in the presence of infection unless effective chemotherapy is also employed. Adverse reactions As with all topical corticosteroids, if the Betnovate preparations are used in large amounts, or for prolonged periods, the possibility of systemic absorption should be considered, especially in children. Prolonged corticosteroid therapy may cause local atrophy.

Method of use Ointment: apply a small amount of ointment two or three times a day initially, using the applicator if internal administration is required. When inflammation is subsiding, once daily application is sufficient in most cases. One tube should provide treatment for at least a week. Suppositories: insert a suppository night and morning.

Legal restriction To be supplied on prescription only. (Therapeutic

Substances Act : Part II)		
Presentation	Ointment	
		Suppository
Betamethasone valerate	0-05%	0-5 mg
Phenylephrine hydrochloride	0.1%	2-0 mg
Lignocaine hydrochloride	2.5%	40-0 mg
	Ba	sic NHS cost
Betnovate Compound Support	sitories	
Box of 10		7/6

Betnovate Compound Suppositories	
Box of 10	7/6
Betnovate Rectal Ointment	
20 gram tube	7/6









HC 6400/NHS-OP/Aug 1969 Betnovate is a Glaxo trade mark